Nishi MD - Climb Bio Senior Development
| CLYM Stock | 1.74 0.04 2.35% |
Executive
Nishi MD is Senior Development of Climb Bio
| Phone | 866 857 2596 |
| Web | https://climbbio.com |
Climb Bio Management Efficiency
The company has return on total asset (ROA) of (0.1895) % which means that it has lost $0.1895 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6204) %, meaning that it created substantial loss on money invested by shareholders. Climb Bio's management efficiency ratios could be used to measure how well Climb Bio manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joe Bruzek | Cars Inc | N/A | |
| Sarah Archibong | Cars Inc | N/A | |
| Michael Crowley | Boston Beer | 55 | |
| Kobe Wang | Li Auto | N/A | |
| Angelique Marks | Cars Inc | 57 | |
| Oksana Dominach | Constellation Brands Class | 60 | |
| Yang Wang | Li Auto | N/A | |
| Lisa Gosselin | Cars Inc | N/A | |
| Paula Erickson | Constellation Brands Class | 56 | |
| Patrick Masterson | Cars Inc | N/A | |
| Matthew Murphy | Boston Beer | 56 | |
| Philip Hodges | Boston Beer | 59 | |
| Joseph Suarez | Constellation Brands Class | N/A | |
| Paul Flynn | Gentex | 60 | |
| Kevin Biddle | Dana Inc | 70 | |
| James Rogers | Cars Inc | 67 | |
| Julien Schneider | Cars Inc | N/A | |
| John Geist | Boston Beer | 64 | |
| Andrea Siudara | Dana Inc | 51 | |
| Craig Price | Dana Inc | N/A | |
| Josh OBerski | Gentex | N/A | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.19 |
Climb Bio Leadership Team
Elected by the shareholders, the Climb Bio's board of directors comprises two types of representatives: Climb Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Climb. The board's role is to monitor Climb Bio's management team and ensure that shareholders' interests are well served. Climb Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Climb Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jo PalmerPhillips, Chief Officer | ||
| Chandra JD, VP Counsel | ||
| Emily CPA, Senior Officer | ||
| Cindy MBA, Senior Finance | ||
| Emily Pimblett, Chief Officer | ||
| Nishi MD, Senior Development | ||
| MD MBA, Treasurer, COO | ||
| Janaki MSc, VP Affairs | ||
| Perrin BS, Chief Officer | ||
| Kate MBA, Senior Management | ||
| BAO BCh, President CEO | ||
| William Bonificio, Interim Officer | ||
| MSc MD, Chief Officer |
Climb Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Climb Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (11.77 M) | ||||
| Shares Outstanding | 67.58 M | ||||
| Shares Owned By Insiders | 7.95 % | ||||
| Shares Owned By Institutions | 84.98 % | ||||
| Number Of Shares Shorted | 1.38 M | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (30.36 M) | ||||
| Net Income | (73.9 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.